Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Menthone [10458-14-7]

Menthone [10458-14-7]

Imprimer Imprimer
Identifiez-vous
Commande minimum 2

Référence HY-N2381-1mL

Conditionnement : 10mM/1mL

Marque : MedChemExpress

Contactez votre distributeur local :


Téléphone : +1 850 650 7790

Description

Menthone, an orally active monoterpene that can be isolated from plants and Mentha oil with antibacterial, antitumor, antioxidation, and antivirus properties. Menthone is a main volatile component of the essential oil, and has anti-Inflammatory properties in Schistosoma mansoni infection and rheumatoid arthritis[1][2].

IC50 & Target

Schistosome

 

In Vitro

Menthone (0.05-500 μM, 48 h) has optimal concentration for murine primary lung mast cells viability are 0.5, 5 and 50 μM[3].
Menthone (0.5-50 μM, 48 h) inhibits the secretion of proinflammatory cytokine TNF-α and have anti-inflammatory potential to LPS-stimulated lung mast cells[3].
Menthone (100 μM, 24 h) inhibits activation of the key transcription factor STAT1 of IFN-I signaling and promotes Tyk2 polyubiquitination to reduce Tyk2 protein levels in 2fTGH cells[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Menthone Related Antibodies

Western Blot Analysis[4]

Cell Line: 2fTGH
Concentration: 100 μM
Incubation Time: 24 h
Result: Decreased the protein levels of these two ISGs (IFIT1 and PKR) induced by IFN-α.
Reduced the levels of p-STAT1 in the nucleus.
Attenuated menthoneinduced degradation of Tyk2 protein by MG132.
Upregulated K48-linked/K63-linked polyubiquitination of Tyk2.
In Vivo

Menthone (100 mg/kg, Articulus injection, 14 days) inhibits the expression of Th1 and Th17 cells in CIA mouse model[1].
Menthone (8-200 mg/kg, i.g. , daily, 5 weeks) improves the allergic inflammatory statu of the lungs and airways in OVA-sensitized and challenged allergic asthmatic inflammation mouse model by modulating the Th2-biased immune balance and mitigating mast cell degranulation[3].
Menthone (100 mg/kg, Articulus injection, 14 days) contributes to the relief of local inflammation of rheumatoid arthritis in CIA mice[1][4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: OVA-sensitized and challenged allergic asthmatic inflammation mouse model [3]
Dosage: 8-200 mg/kg
Administration: i.g., daily, 5 weeks
Result: Reversed the allergic inflammation status through at medium and high doses.
Decreased total cell number and eosinophilia into BALF.
Increased the percentage of monocytes/macrophages and Th1 (IL-2+IFN-γ)/Th2 (IL-4+IL-5) cytokine secretion ratio in BALF.
Decreased the levels of otaxin and protein in BALF and reduced the release of β-hexosaminidase from lung mast cells.
Inhibited CC receptor 3 and CXC receptor 1 gene expression levels.
Animal Model: CIA mouse model[1][4]
Dosage: 100 mg/kg
Administration: Articulus injection, 14 days
Result: Decreased degree of posterior palm swelling and alleviated the inflammation in the local knuckles .
Increased the levels of serum Creactive protein (CRP).
Decreased the levels of ISGs (Ifit1, Isg15, and Mx1) and proinflammatory cytokines (TNF-α, IL-6, and IL-1β) in the finger joint tissues of the mice.
Decreased the number of Th1 and Th17 cells.
Decreased the levels of T-bet and RORγT gene transcription and increased the levels of GATA3 and Foxp3.
Didn't produce severe hepatorenal toxicity.
Masse moléculaire

154.25

Formule

C10H18O
CAS No.
Appearance

Liquid (Density: 0.896 g/cm3)

Color

Colorless to light yellow

SMILES

O=C1C(C(C)C)CCC(C)C1
Structure Classification
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvant et solubilité
In Vitro: 

DMSO : 100 mg/mL (648.30 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 6.4830 mL 32.4149 mL 64.8298 mL
5 mM 1.2966 mL 6.4830 mL 12.9660 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (16.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (16.21 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Pureté et documentation
Références